Search

Your search keyword '"Basak Adakli Aksoy"' showing total 6 results
Start Over Author "Basak Adakli Aksoy"
6 results on '"Basak Adakli Aksoy"'

1. STEM CELL TRANSPLANTATION AS A TREATMENT OPTION FOR RELAPSED/REFRACTORY GERM CELL TUMORS

Author

Başak Adaklı Aksoy

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Malignant germ cell tumors (GT) arise from abnormal migration of primordial germ cells and are histologically identical whether they occur inside or outside of central nervous system (CNS) (1). They are divided into two heterogenous groups: germinomas and non-germinomatous germ cell tumors according to histological findings. Although the optimal treatment strategy remains a matter of debate, they generally respond well to surgery, radiotherapy, chemotherapy, or a combination of all and are characterized by a good survival rate (2). The surgical strategy for GCTs varies depending on the location of the tumor. Surgery is only a standard care option for low grade extracranial GCTs because it is unlikely to achieve negative tumor margins when the tumor is located inside CNS (2). Patients with relapsed or progressive despite initial chemotherapy are candidates for salvage therapy (3). Patients relapsing after definite treatment of locoregional disease are to be treated by stage adopted first line standard therapy for metastatic disease. Patients with primary advanced/metastatic disease failing one line of cisplatin based combination chemotherapy can benefit from high dose chemotherapy and stem cell rescue (4). Although stem cell transplantation following high dose chemotherapy can be beneficial, either two or three consecutive cycles of high dose chemotherapy with repetition after blood count recovery may contribute to overall survival rates.

Published
2023
Full Text
View/download PDF

3. The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience

Author

Ceyhun Bozkurt, Erdal Karaöz, Başak Adaklı Aksoy, Selime Aydoğdu, and Tunç Fışgın

Subjects
childhood, stem cell transplantation, steroid-resistant acute graft-versus-host disease, mesenchymal stem cell, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Objective: Objective: Steroid-resistant acute graft-versus-host disease (srAGVHD) is the most important cause of morbidity and mortality after allogeneic stem cell transplantation. There are several treatment methods available, including mesenchymal stem cell (MSC) application. The aim of this study was to evaluate the results of MSC therapy performed in children with srAGVHD. Materials and Methods: MSC therapy was used in our center between November 2014 and December 2017 for 22 patients who developed srAGVHD. The patients were retrospectively evaluated in terms of treatment response and survival. Results: After application of MSCs, complete response was obtained in 45.5% of the subjects, partial response was obtained in 13.6%, and no response was obtained in 40.9%. We found that 45.5% of the patients were alive and 54.5% had died and our treatment results were similar to those in the literature. Response to MSC treatment was found to be the only prognostic marker affecting mortality. Conclusion: MSC application is a treatment method that can be used safely together with other treatment methods in srAGVHD, a condition that has a high mortality rate. There are almost no acute side effects. There are also no serious long-term side effects in the literature. Prospective randomized studies are required to obtain high-quality data.

Published
2019
Full Text
View/download PDF

5. The effect of biofilm inhibitor N-acetylcysteine on the minimum inhibitory concentration of antibiotics used in Gram-negative bacteria in the biofilm developed on catheters

Author

Nilay Aksoy, Cansu Vatansever, Gizem Zengin Ersoy, Basak Adakli Aksoy, and Tunç Fışgın

Subjects
Catheters, Colistin, Biomedical Engineering, Medicine (miscellaneous), Bioengineering, Meropenem, Microbial Sensitivity Tests, General Medicine, Ceftazidime, Acetylcysteine, Anti-Bacterial Agents, Biomaterials, Biofilms, Gram-Negative Bacteria, Pseudomonas aeruginosa, Escherichia coli, Humans, Cefepime, Child, Amikacin
Abstract

The study determined the effect of N-acetylcysteine (NAC) on the susceptibility of various antibiotics used to treat Gram-negative catheter-related infection in isolates obtained from pediatric patients admitted to the hematology and oncology department of Medical Park Bahçelievler hospital in Istanbul, Turkey. Biofilms were created in vitro utilizing clinical isolates of Escherichia coli, Pseudomonas aeruginosa, Pseudomonas putida, and Proteus mirabilis. 24 h old biofilms were developed on 96-well plate with strains and the minimum biofilm inhibitory concentration (MBIC) of six antibiotics were measured before and after the addition of 75 mg/ml N-acetylcysteine with microplate reader at 450 nm after crystal violet assay. The addition of NAC reduce the MBIC of cefepime, ceftazidime, colistin, meropenem from (16, 16, 8, 4 μg/ml) to (8, 4, 4, 2 μg/ml) respectively in E. coli (isolate 1). In P. aeruginosa (isolate 4), the MBIC of amikacin, ceftazidime, meropenem (64, 32, and 32 μg/ml) reduced to (8, 1, and 0.5 μg/ml) respectively. MBIC of cefepime, colistin, meropenem (32, 16,and 16 μg/ml) reduced to (2, 2,and 0.5 μg/ml) respectively in P. putida (isolate 5). In P. mirabilis (isolate 6), MBIC of amikacin, cefepime, ceftazidime, colisitin and meropenem (64, 128, 32, 4, and 32 μg/ml) reduced to (8, 8, 1, 1, 4 μg/ml). NAC in combination therapy can practically reduce the MBIC of antibiotics used to treat Gram negative bacteria that develop biofilm in medical catheters. As a result, these combinations can be considered as an essential alternative for increasing the antibiotic susceptibility of pathogenic microorganisms and thus increasing treatment success rates.

Published
2022

6. Evaluation of the risk factors for <scp>BK</scp> virus‐associated hemorrhagic cystitis in pediatric bone marrow transplantation patients: Does <scp>post‐transplantation</scp> cyclophosphamide increase the frequency?

Author

Gizem Zengin Ersoy, Ceyhun Bozkurt, Basak Adakli Aksoy, Özlem Başoğlu Öner, Selime Aydoğdu, Funda Çipe, Murat Sütçü, Ozan Özkaya, Tunç Fışgın, İstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Murat Sütçü / 0000-0002-2078-9796, Özkaya, Ozan, Sütçü, Murat, Murat Sütçü / AAR-5212-2020, Ozan Özkaya / AAO-2136-2020, Murat Sütçü / 55499199300, and Ozan Özkaya / 7003365098

Subjects
BK Virus Hemorrhagic Cystitis, Transplantation, Post Transplantation Cyclophosphamide, Pediatrics, Perinatology and Child Health, Stem Cell Transplantation
Abstract

Background: BKV-HC is one of the most significant complications of HSCT. This ret -rospective study aimed to determine the frequency of BKV-HC in pediatric patients undergoing HSCT, detect the associated risk factors for the development of BKV-HC, and explore the effects of post-transplantation Cy use.Methods: Three hundred twenty-seven patients (girls: 121, boys: 206) were analyzed according to sex, conditioning regimen, transplantation type, donor relatedness, stem cell source, the presence and grade of aGVHD, CMV co-existence, and Cy use.Results: Multivariate analysis confirmed the prognostic importance of age (OR: 4.865), TBI use, the presence of aGVHD (OR: 2.794), CMV coinfection (OR: 2.261), and Cy use (OR: 27.353). A statistically significant difference was found between the mean BKV-HC follow-up times compared with post-transplantation Cy intake (p< .001). The BKV-HC rate increased as the number of risk factors of the patient increased.Conclusion: BKV-HC is an essential complication of HSCT primarily associated with Cy use, the presence of aGVHD, and donor relatedness. The present study shows that the use of Cy in the post-transplantation period further increases BKV-HC risk in pediatric patients, regardless of dose. 35851981

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results